KRAS and non-small cell lung carcinoma: Schoenfeld and colleagues identified two clinically distinct classes of SMARCA4 alterations in metastatic NSCLC, both significantly enriched in tumors co-mutated with KRAS, STK11, and KEAP1, compared to SMARCA4 wild-type (p < 0.001), [28].